

UNITED STATES DISTRICT COURT
DISTRICT OF NEW JERSEY

IN RE: VALSARTAN, LOSARTAN,
AND IRBESARTAN PRODUCTS
LIABILITY LITIGATION

:
:
:
:
:
:
:
:
:
:
:
:

Hon. Robert B. Kugler

Civil No. 1:19-md-2875-RBK-JS

This Document Relates to:

All Actions

:

CORPORATE DISCLOSURE

Pursuant to Federal Rule of Civil Procedure 7.1, Defendant Prime Therapeutics, LLC (“Prime”), by and through the undersigned attorneys, hereby makes the following disclosure:

Prime certifies that it has no parent corporation and no publicly held corporation owns 10% or more of its stock.

/s/ Anna María Tejada

Anna María Tejada, Esq.
Saul Ewing Arnstein & Lehr LLP
1037 Raymond Blvd.
Suite 1520
Newark, New Jersey 07102
Phone: (973) 286-6727
Email: annamaria.tejada@saul.com

Attorney for Prime Therapeutics LLC

CERTIFICATE OF SERVICE

I certify that on March 8, 2021, a true and correct copy of the foregoing document was electronically filed with the Clerk of the United States District Court and forwarded electronically to all counsel of record *via* the CM/ECF system.

/s/ Anna María Tejada

Anna María Tejada, Esq.